June 2019: Annual General Meeting 2019

June 2019: Annual General Meeting 2019

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2019. The Annual General Meeting will be held on Tuesday, June 25th  2019 at 04:30 pm (registration at 04:00 pm) in the Careum Auditorium – Pestalozzistrasse 11, 8032 Zürich. Shareholders will be admitted…

May 2019: Talidox better tolerated than expected

May 2019: Talidox better tolerated than expected

On May 14, 2019, the sixth patient was treated with Talidox at the Inselspital Bern. The dose of 40mg/m2 now reached already corresponds to the maximum dose originally planned in the study. The latter was defined on the basis of…

April - May 2019: CAPITAL INCREASE WITH PUBLIC OFFERING

April – May 2019: CAPITAL INCREASE WITH PUBLIC OFFERING

Capital increase with public offering of 103,516 bearer shares / CHF 23,456,725.60 The subscription ends May 31st 2019. Share price is CHF 226.60 per new share (minimum 60 shares).   Visit us at an investor event in Bern, Zurich, Basel, St. Gallen,…

January 2019: Resignations from the Board of Directors

The two Board members Dr. Herbert Früh and Manuel Frick resigned from the Board of Directors of InnoMedica Holding AG as of mid-January 2019. Herbert Früh has been a member of the Board of Directors since 2000 and acting as…

December Update 2018

December Update 2018

Thanks to the successful financing round of CHF 10.25 million in May 2018, the InnoMedica team reached an important milestone with Talidox with the start of the clinical trial and made strategically relevant progress in clinical development and raw material…

November 2018: Start of the clinical trial with Talidox

November 2018: Start of the clinical trial with Talidox

Swissmedic has approved the clinical study phase I with Talidox. After production met all pharmaceutical standards, InnoMedica’s quality assurance released Talidox for clinical use. Last Monday, November 12, 2018, the first cancer patient was treated with Talidox at the Cantonal…

June 2018: Annual General Meeting 2018

June 2018: Annual General Meeting 2018

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2018. The Annual General Meeting will be held on Tuesday, June 26th  2018 at 04:30 pm (doors open at 04:15 pm) in the Careum Auditorium – Pestalozzistrasse 11, 8032 Zürich. Shareholders…

June 2018: New capital of CHF 10.25 million

June 2018: New capital of CHF 10.25 million

The 2018 capital increase was closed on May 31 with subscriptions in the amount of CHF 10.25 million. As in previous financing rounds, we were able to substantially expand our shareholder base also this year and now count around 640…

March - May 2018: Capital increase with public offering

March – May 2018: Capital increase with public offering

Capital increase with public offering of 153,272 bearer shares / CHF 31,574,032 The subscription ends May 31st 2018. Share price is CHF 206 per new share (minimum 75 shares).   Visit us at an investor event in Bern, Zurich, Basel,…

Update December 2017

Thanks to the successful financing round of CHF 7.7 million in May 2017, the InnoMedica team has achieved significant progress with Talidox in recent months and further developed a new liposomal application in the field of neurodegenerative diseases into a…